Insmed reported $403.69M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
BioMarin Pharmaceutical USD 807.82M 259.3M Sep/2025
Cytokinetics USD 168.69M 9.58M Sep/2025
DBV Technologies USD 37.05M 4.06M Sep/2025
Dynavax Technologies USD 73.6M 7.41M Sep/2025
Gilead Sciences USD 4.26B 95M Sep/2025
Insmed USD 403.69M 42.4M Sep/2025
Novartis USD 9.77B 401M Sep/2025
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Sarepta Therapeutics USD 462.23M 33.28M Sep/2025
Ultragenyx Pharmaceutical USD 330.82M 56.44M Sep/2025
Vertex Pharmaceuticals USD 1.84B 27.1M Sep/2025